Institute for Cancer Research


Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more

Harald Stenmark<br>Acting Inst. Head
Harald Stenmark
Acting Inst. Head

Scientific production - Institute for Cancer Research

  Publications Doctoral theses
2017 so far  
 2016 235  15
2015 221 21
2014 174 25

Annual report 2015 (pdf format)


Latest news

OUH scientists involved in sequencing study of osteosarcoma that has identified mutations in IGF signalling genes

From left: Zaikova, Bjerkehagen and Myklebost
From left: Zaikova, Bjerkehagen and Myklebost

A portion of bone cancers may respond to existing insulin-like growth factor 1 receptor inhibitors because they carry mutations in IGF signaling genes, a study recently published in Nature Communications suggests. The sarcoma team at the Norwegian Radium Hospital at Oslo University Hospital was represented in this study by Bodil Bjerkehagen, the sarcoma reference pathologist, Olga Zaikova, on behalf of the orthopedists, and Ola Myklebost, PI in the ICGC Bone Cancer Project. This study is a side branch from their previous participation in the European Network of Excellence on Bone Tumours, and is carried out by the International Cancer Genomics Consortium at the Sanger Centre in Hinxton outside Cambridge.


Call for applications 2018

Annuncement of research funding from South-East Norway regional health authority for 2018


The South-Eastern Norway Regional Health Authority hereby announces a call for applications for research projects and research activities starting in 2018.

The total funding available for this call is approximately 100 million Norwegian kroner.

Application deadline is Tuesday, September 5th 2017 kl. 16:00.


Oslo University Hospital has awarded 6 excellent articles for the second half-year of 2016

Award winners during the ceremony (photo Marethe Falch)
Award winners during the ceremony (photo Marethe Falch)

Six research groups were awarded for their excellent papers published during the second half-year of 2016 during a ceremony June 16th. Each group received NOK 50.000 for use in further research. The prize winners gave short presentations of the main findings in their respective articles.

The six selected articles are of especially high quality, and they present important finding on both-short and long-term scales. The works reflect the good quality and the interdisciplinarity that characterises several research environments at Oslo University Hospital. The research is a fundamental condition for the institution to maintain and strenghten the quality in the patient treatment.


Øyvind S. Bruland appointed "Innovator of the Month" by Helse Sør-Øst

Øyvind S. Bruland
Øyvind S. Bruland

Professor Øyvind Sverre Bruland, senior consultant oncologist at the Department of Oncology at the Division of Cancer Medicine, has been interviewed in connection with being appointed "Innovator of the Month" by South-Eastern Norway Regional Health Authority (Helse Sør-Øst). His clinical experience and research are mainly devoted to primary bone and soft tissue cancers (sarcomas) and skeletal metastases from prostate cancer and breast cancer. In particular, targeted radionuclide therapy, e.g. Alpharadin (Algeta), based on Radium-223, is currently at center stage.


Innovation project from the Lind group featured by GenomeWeb


The New York based news organization GenomeWeb recently presented an in-depth article about the Oslo University Hospital-efforts of developing a urine-based test for monitoring of bladder cancer patients. Professor Guro Lind presented the project at the Oslo Life Science Conference 2017 previously this year (watch presentation, 58 minutes into the recording. The project drew the attention of Bjarne Røsjø in Titan and was later picked up by GenomeWeb.


Clinically important genetic heterogeneity in colorectal cancers with microsatellite instability

First authors Anita Sveen, Torstein Tengs and Bjarne Johannessen (contributed equally)
First authors Anita Sveen, Torstein Tengs and Bjarne Johannessen (contributed equally)

Microsatellite instability (MSI) defines a small subgroup of approximately 15% of colorectal cancers (CRC) which currently receives much attention due to its overall good response to immune-checkpoint inhibition. In the latest issue of Genome Medicine, scientist Anita Sveen and colleagues publish the largest multilevel genetic analysis of this tumor type reported to date, describing substantial inter- and intra-tumor heterogeneity. The clinical importance of these results, in particular with respect to the optimized use of immunotherapeutics for treatment of human cancers, was emphasized in a Research Highlight in the same issue of the journal.